遺伝子融合検査市場 - 世界および地域別分析：カテゴリー別、技術別、適応症別、エンドユーザー別、地域別 - 分析と予測（2025年～2035年）

世界の遺伝子融合検査市場は、分子診断と精密医療の重要な構成要素であり、様々な疾患、特にがんの市場開拓に寄与する遺伝子変化、特に遺伝子融合を特定することに焦点を当てています。

これらの検査は、タンパク質の機能異常を引き起こし、がんの進行を促進する可能性のある遺伝子再配列を検出します。高度な診断技術への需要が高まるにつれ、世界の遺伝子融合検査市場は精密医療に不可欠なものとなり、個々の患者の固有の遺伝子プロファイルに合わせた個別化治療の開発を可能にしています。この市場は、遺伝子所見に基づいてより的を絞った効果的な治療を可能にし、がん治療を変革する上で重要な役割を果たしています。

世界の遺伝子融合検査市場では、次世代シークエンシング（NGS）、蛍光in situハイブリダイゼーション（FISH）、ポリメラーゼ連鎖反応（PCR）などの複数の技術が、さまざまながんにおける遺伝子融合を検出するために使用されています。進歩が続くにつれて、世界の遺伝子融合検査市場は飛躍的に成長し、早期診断、正確な治療選択、患者の転帰改善のための新たな機会を提供すると予想されます。個別化医療に対する需要の高まりは、遺伝子融合検査の世界市場をさらに後押しし、患者の遺伝的体質に合わせた治療を確実に行い、治療効果を高め、副作用を最小限に抑えます。

世界の遺伝子融合検査市場は、遺伝子融合変異に関連するがんの有病率の上昇に後押しされ、大きな成長を遂げています。早期発見、標的療法の的確な選択、個別化医療に対する需要の高まりが、この拡大を後押ししています。さらに、臨床現場における遺伝子融合検査の採用拡大が、がん治療におけるこれらの診断検査の必要性をさらに加速させています。世界の遺伝子融合検査市場が進化を続ける中、遺伝子融合検査は、がん患者により正確で個別化された治療選択肢を可能にし、患者の転帰全体を改善する上で重要な役割を果たしています。

遺伝子融合検査は、遺伝子融合として知られる遺伝子異常を検出・検査するために分子解析を用いる診断法です。遺伝子融合は、異なる染色体領域に存在する2つの異なる遺伝子が異常に結合し、ハイブリッド遺伝子が作られることで起こる。この融合は、異常なタンパク質の産生や遺伝子発現の変化をもたらし、特定のがんを含む様々な疾患の開発に寄与する可能性があります。がんの進行は、突然変異、欠失、増幅、再配列などの複数の遺伝子変化によって影響を受けますが、遺伝子融合は重要な要因です。Amoy Diagnostics Co.Ltd.、Biocartis、Biocare Medical, LLC、Danaher Corporation、F. Hoffmann-La Roche Ltd.などの業界大手企業の関与が、世界の遺伝子融合検査市場のさらなる成長を促進すると期待されています。

さらに、AIを活用した予測モデルは、追加の診断検査を必要とする可能性のある患者を特定することで、時間と費用のかかる検査室アッセイの必要性を最小限に抑える可能性を提供します。これらのモデルはまた、これまで検出されていなかった遺伝子融合イベントを発見し、がんのゲノム状況の理解を向上させ、世界の遺伝子融合検査市場における標的治療アプローチの開発を支援する可能性があります。

カテゴリー別では、調査セグメントが2024年度の世界の遺伝子融合検査市場をリードすると予測されます。キット、アッセイ、付属品の採用が増加していることが、このセグメントの成長と優位性に大きく寄与しています。これらの研究専用アッセイやキットは、主に診断用途というよりも研究環境での使用を目的として設計されており、遺伝子融合と様々な疾患（特にがん）への関与を研究する科学者や研究者にとって不可欠です。これらのツールに対する需要が増加し続けていることから、研究セグメントは世界の遺伝子融合検査市場において支配的な地位を維持するものと思われます。

技術別では、NGS（次世代シーケンシング）分野が2024年度の世界の遺伝子融合検査市場を独占すると予測されています。NGSは、DNAおよびRNA配列のハイスループットかつ正確な分析を提供し、遺伝子融合検査において極めて重要な役割を果たす先進的かつ変革的な技術です。遺伝子融合検査の文脈では、NGSは遺伝子再配列の包括的な検査を容易にし、異なる遺伝子間の融合事象を卓越した精度で正確に同定することを可能にします。NGSは進化を続けており、世界の遺伝子融合検査市場において主導的地位を維持するものと思われます。

適応症別では、固形腫瘍分野が2024年度に世界の遺伝子融合検査市場をリードすると予測されています。腫瘍学では、固形腫瘍の遺伝子融合検査は分子診断学において極めて重要であり、腫瘍細胞内の染色体再配列や転座によって引き起こされる特定の遺伝子融合を特定することに焦点を当てています。これらの遺伝子融合は異常な融合タンパク質の産生をもたらし、固形がんの進行と開発に重要な役割を果たします。精密ながん診断の需要が高まるにつれ、固形がん分野は世界の遺伝子融合検査市場において優位性を維持すると予想されます。

エンドユーザー別では、製薬・バイオテクノロジー企業が2024年度の世界遺伝子融合検査市場で最大のシェアを占めると予想されます。これらの企業は、急速に発展するこの分野における技術革新を推進し、進歩を促進するために、その専門知識とリソースを活用し、市場で重要な役割を果たしています。遺伝子融合検査の大きな可能性を深く理解している製薬企業やバイオテクノロジー企業は、がん診断や治療戦略に革命を起こす取り組みを主要企業として主導しており、遺伝子融合検査世界市場の継続的な成長と開拓を確実なものにしています。

欧州市場はドイツが独占的であり、英国が最も高い成長率を示すと予測されています。英国は遺伝子融合検査技術の開発に協力的なアプローチを採用しています。さらに、同国は学術研究機関が充実していることでも知られており、遺伝子検査技術の進歩や世界の遺伝子融合検査市場における技術革新の推進に重要な役割を果たしています。

遺伝子融合検査市場は、遺伝子融合の検出と解析を目的とした検査や技術の開発、生産、商業化に特化した、ヘルスケア産業における重要なセグメントです。この検査は、2つの異なる遺伝子が融合し、機能が改変された融合タンパク質を形成する異常な融合事象を同定するものであり、多くの場合、様々な疾患、特にがんに関連しています。この研究では、ポリメラーゼ連鎖反応（PCR）、次世代シークエンシング（NGS）、免疫組織化学（IHC）、蛍光in-situハイブリダイゼーション（FISH）など、遺伝子融合検査の進歩を牽引してきたいくつかの中核技術を調査します。世界の遺伝子融合検査市場の拡大は、革新的技術の継続的な導入と、政府および民間部門両方からの投資および資金調達の増加によって促進されています。

ワークフロー/イノベーション戦略：遺伝子融合検査市場は、適応症別に固形がんと血液悪性腫瘍に区分されます。さらに、本調査では固形がんにおける遺伝子融合検査の多様な応用について徹底的な分析を行い、これらの特定のがん種に関連する遺伝子融合を同定する際の役割について読者に包括的な理解を提供しています。

成長／マーケティング戦略：遺伝子融合検査は、がん細胞における特定の遺伝子変化を同定・解析するために用いられる分子診断技術です。通常、異なる染色体上に位置する2つの異なる遺伝子が異常に融合し、機能が改変されたユニークなタンパク質を生成するハイブリッド遺伝子が作られることで発生します。

競合戦略：本調査では、世界の遺伝子融合検査市場における主要企業（メーカーを含む）を幅広く分析し、プロファイリングしています。さらに、これらの参入企業の詳細な競合ベンチマーキングを実施し、読者に各社が互いにどのように比較しているかを明確に考察し、市場情勢の包括的な見解を示しています。

当レポートでは、世界の遺伝子融合検査市市場について調査し、市場の概要とともに、カテゴリー別、技術別、適応症別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 製品定義

第2章 市場の範囲

第3章 調査手法

第4章 市場概要

• 遺伝子融合検査のイントロダクション
  • 遺伝子融合検査のためのさまざまな技術
  • 遺伝子融合検査の利点と限界
  • 現在の市場規模と将来の成長可能性（100万米ドル、2023年～2035年）
  • 遺伝子融合検査における人工知能（AI）と機械学習（ML）の役割
  • 償還の情勢
• ステークホルダーの調査回答
  • 遺伝子融合検査に関する認識
  • 以下の企業のNGSサービスに関する知識
  • 遺伝子融合検査の導入と障壁

第5章 業界展望

• 規制状況
  • 米国における法的要件と枠組み
  • 欧州における法的要件と枠組み
  • アジア太平洋における法的要件と枠組み

第6章 世界の遺伝子融合検査市場：市場力学

• 影響分析
• 市場促進要因
• 市場抑制要因
• 市場機会

第7章 世界の遺伝子融合検査市場：競合考察

• 概要
• 主要戦略と開発
  • 製品の承認と発売
  • パートナーシップとコラボレーション
  • 合併と買収
  • その他の展開
• 市場シェア分析
  • 企業別
• 成長シェア分析

第8章 世界の遺伝子融合検査市場、カテゴリー別、（100万米ドル）、2023年～2035年

• 概要
• 研究
• 診断

第9章 世界の遺伝子融合検査、技術別、（100万米ドル）、2023年～2035年

• 概要
• 次世代シーケンシング（NGS）
• 蛍光in-situハイブリダイゼーション（FISH）
• ポリメラーゼ連鎖反応（PCR）
• 免疫組織化学（IHC）

第10章 世界の遺伝子融合検査市場、適応症別、（100万米ドル）、2023年～2035年

• 概要
• 固形腫瘍
  • 肺がん
  • 乳がん
  • 大腸がん
  • 甲状腺がん
  • その他
• 造血悪性腫瘍

第11章 世界の遺伝子融合検査市場、エンドユーザー別、（100万米ドル）、2023年～2035年

• 概要
• 製薬およびバイオテクノロジー企業
• 病院および診断検査室
• 研究・学術センター

第12章 世界の遺伝子融合検査市場、地域別、（100万米ドル）、2023年～2035年

• 概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• その他の地域

第13章 競合情勢と企業プロファイル

• 競合情勢
• Amoy Diagnostics Co., Ltd.
• Arima Genomics
• Biocartis
• Biocare Medical, LLC
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Guardant Health, Inc
• Illumina, Inc.
• Invitae Corporation
• Myriad Genetics, Inc.
• NeoGenomics, Inc.
• OncoDNA
• PerkinElmer, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

List of Figures

• Figure: Global Gene Fusion Testing Market, Dynamics Impact Analysis
• Figure: Global Gene Fusion Testing Market Coverage
• Figure: Global Gene Fusion Testing Market, Key Trends, Impact Analysis, 2023-2035
• Figure: Global Gene Fusion Testing Market, Patent Analysis, January 2022-March 2025
• Figure: Global Gene Fusion Testing Market, Competitive Landscape, January 2022-March 2025

List of Tables

• Table: Global Gene Fusion Testing Market Dynamics, Impact Analysis
• Table: Global Gene Fusion Testing Market (by Category), $Million, 2023-2035
• Table: Global Gene Fusion Testing Market (by Technology), $Million, 2023-2035
• Table: Global Gene Fusion Testing Market (by Indication), $Million, 2023-2035
• Table: Global Gene Fusion Testing Market (by End User), $Million, 2023-2035

Global Gene Fusion Testing Market Industry Overview

The global gene fusion testing market is a critical component of molecular diagnostics and precision medicine, focused on identifying genetic alterations, specifically gene fusions, that contribute to the development of various diseases, particularly cancer. These tests detect gene rearrangements that may lead to abnormal protein functions, driving cancer progression. As the demand for advanced diagnostic technologies grows, the global gene fusion testing market has become essential in precision medicine, enabling the development of personalized treatments tailored to the unique genetic profiles of individual patients. This market plays a vital role in transforming cancer care, allowing for more targeted and effective therapies based on genetic findings.

In the global gene fusion testing market, several technologies such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) are used to detect gene fusions in various cancers. As advancements continue, the global gene fusion testing market is expected to grow exponentially, offering new opportunities for early diagnosis, precise treatment selection, and improved patient outcomes. The rising demand for personalized medicine further propels the global gene fusion testing market, ensuring that patients receive treatments tailored to their genetic makeup, enhancing the effectiveness of therapies and minimizing side effects.

Market Lifecycle Stage

The global gene fusion testing market is experiencing significant growth, fueled by the rising prevalence of cancer associated with gene fusion mutations. The increasing demand for early detection, precise selection of targeted therapies, and personalized medicine is driving this expansion. Additionally, the growing adoption of gene fusion testing in clinical practice is further accelerating the need for these diagnostic tests in cancer care. As the global gene fusion testing market continues to evolve, it plays a crucial role in enabling more accurate and individualized treatment options for cancer patients, improving overall patient outcomes.

Impact

Gene fusion testing is a diagnostic method that employs molecular analysis to detect and examine genetic abnormalities known as gene fusions. These occur when two distinct genes from different chromosomal regions become abnormally joined, creating a hybrid gene. This fusion can result in the production of abnormal proteins or changes in gene expression, potentially contributing to the development of various diseases, including certain cancers. Cancer progression is influenced by multiple genetic alterations, such as mutations, deletions, amplifications, and rearrangements, with gene fusions being a key factor. The involvement of leading industry players, including Amoy Diagnostics Co., Ltd., Biocartis, Biocare Medical, LLC, Danaher Corporation, and F. Hoffmann-La Roche Ltd., is expected to drive further growth in the global gene fusion testing market.

In addition, AI-powered prediction models offer the potential to minimize the need for time-consuming and expensive laboratory assays by identifying patients who may require additional diagnostic testing. These models could also uncover previously undetected gene fusion events, improving the understanding of the genomic landscape of cancers and supporting the development of targeted therapeutic approaches in the global gene fusion testing market.

Market Segmentation:

Segmentation 1: by Category

• Research
• Diagnostic

Research to Continue its Dominance in the by Category Segment

In terms of category type, the research segment is anticipated to lead the global gene fusion testing market in FY2024. The increasing adoption of kits, assays, and accessories has greatly contributed to the growth and prominence of this segment. These research-specific assays and kits, primarily designed for use in research settings rather than diagnostic applications, are vital for scientists and researchers studying gene fusions and their involvement in various diseases, especially cancer. As demand for these tools continues to rise, the research segment is set to maintain its dominant position in the global gene fusion testing market.

Segmentation 2: by Technology

• NGS
• FISH
• PCR
• IHC

NGS to Continue its Dominance in the Technology Segment

Based on technology, the NGS (Next-Generation Sequencing) segment is projected to dominate the global gene fusion testing market in FY2024. NGS is an advanced and transformative technology that plays a pivotal role in gene fusion testing, providing high-throughput and accurate analysis of DNA and RNA sequences. In the context of gene fusion testing, NGS facilitates a comprehensive examination of genetic rearrangements, enabling the precise identification of fusion events between different genes with exceptional accuracy. As NGS continues to evolve, it is set to maintain its leading position in the global gene fusion testing market.

Segmentation 3: by Indication

• Solid Tumors
• Hematological Malignancies

Solid Tumors to Continue its Dominance in the Indication Segment

Based on indication, the solid tumors segment is anticipated to lead the global gene fusion testing market in FY2024. In oncology, gene fusion testing for solid tumors is crucial in molecular diagnostics, focusing on identifying specific gene fusions caused by chromosomal rearrangements or translocations within tumor cells. These gene fusions can result in the production of abnormal fusion proteins, which play a significant role in the progression and development of solid tumors. As the demand for precise cancer diagnostics increases, the solid tumors segment is expected to maintain its dominance in the global gene fusion testing market.

Segmentation 4: by End User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Academic and Research Centers

Pharmaceutical and Biotechnology Companies to Continue its Dominance in the End User Segment

Based on end user, the pharmaceutical and biotechnology companies segment is expected to hold the largest share of the global gene fusion testing market in FY2024. These companies play a crucial role in the market, utilizing their expertise and resources to drive innovation and promote advancements in this rapidly evolving field. With a keen understanding of the significant potential of gene fusion testing, pharmaceutical and biotechnology companies are leading efforts to revolutionize cancer diagnostics and treatment strategies, ensuring continued growth and development in the global gene fusion testing market.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

U.K. to Continue its Dominance as the Leading Country in Europe Region

Germany is the dominant market in Europe, with the U.K. projected to experience the highest growth rate. The U.K. has adopted a supportive approach towards the development of gene fusion testing technologies. Furthermore, the country is known for its robust academic and research institutions, which play a critical role in advancing genetic testing technologies and driving innovation in the global gene fusion testing market.

Demand - Drivers and Limitations

Market Demand Drivers:

• Growing Prevalence of Cancer Driven by Gene Fusion Mutations
• Expanding Use of Gene Fusion Testing in Targeted Therapy Development
• Global Increase in Research Funding Focused on Cancer Screening and Prevention

Market Restraints:

• Challenges Due to the Complexity of the Testing Process
• Issues with Standardization and Barriers in Reimbursement Policies

Market Opportunities:

• Growing Demand for Gene Fusion Testing in Clinical Research
• Utilizing Artificial Intelligence to Predict Gene Fusion Status Across Various Cancer Types

The gene fusion testing market is a crucial segment within the healthcare industry, dedicated to the development, production, and commercialization of tests and technologies aimed at detecting and analyzing gene fusions. This testing identifies abnormal fusion events where two distinct genes merge to form fusion proteins with modified functions, often linked to various diseases, particularly cancer. This study explores several core technologies that have driven advancements in gene fusion testing, including polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in-situ hybridization (FISH). The expansion of the global gene fusion testing market is fueled by the ongoing introduction of innovative technologies and increasing investments and funding from both government and private sectors.

How can this report add value to an organization?

Workflow/Innovation Strategy: The gene fusion testing market, segmented by indication, comprises solid tumors and hematological malignancies. Furthermore, the study provides a thorough analysis of the diverse applications of gene fusion testing in solid tumors, offering readers a comprehensive understanding of its role in identifying gene fusions linked to these specific cancer types.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic technique employed to identify and analyze specific genetic alterations in cancer cells. It occurs when two distinct genes, typically located on different chromosomes, fuse abnormally, creating a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the global gene fusion testing market have been extensively analyzed and profiled in this study, including manufacturers. Furthermore, a detailed competitive benchmarking of these players has been performed to give readers a clear insight into how companies measure up against each other, presenting a comprehensive view of the market landscape.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Detailed secondary research to ensure maximum coverage of manufacturers/suppliers operational in a country.
• Exact revenue information, up to a certain extent, will be extracted for each company from secondary sources and databases. Revenues specific to product/service/technology will then be estimated for each market player based on fact-based proxy indicators as well as primary inputs.
• The currency conversion rate has been taken from the historical exchange rate of Oanda and/or other relevant websites.
• Any economic downturn in the future has not been taken into consideration for the market estimation and forecast.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year.
• The term "product" in this document may refer to "service" or "technology" as and where relevant.
• The term "manufacturers/suppliers" may refer to "service providers" or "technology providers" as and where relevant.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Food and Drug Administration (FDA), European Medical Agency (EMA), National Medical Product Administration (NMPA), Ministry of Health, Labor, and Welfare (MHLW), Pharmaceutical and Medical Devices Association (PMDA), Frontiers, and World Intellectual Property Organization (WIPO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

• Amoy Diagnostics Co., Ltd.
• Biocartis
• Biocare Medical, LLC
• F. Hoffmann-La Roche Ltd
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

1. Product definition

• 1.1 Inclusion and Exclusion Criteria

2. Market Scope

• 2.1 Scope of the Study
• 2.2 Key Questions Answered in the Report

3. Research Methodology

4. Market Overview

• 4.1 Introduction to Gene Fusion Testing
  • 4.1.1 Different Technologies for Gene Fusion Testing
  • 4.1.2 Advantages and Limitations of Gene Fusion Testing
  • 4.1.3 Current Market Size and Future Growth Potential, $Million, 2023-2035
  • 4.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
  • 4.1.5 Reimbursement Landscape
• 4.2 Stakeholder's Survey Response
  • 4.2.1 Awareness of Gene Fusion Testing
  • 4.2.2 Familiarity with the NGS Offerings of the Following Companies
  • 4.2.3 Adoption and Barriers for Gene Fusion Testing

5. Industry Outlook

• 5.1 Regulatory Landscape
  • 5.1.1 Legal Requirements and Frameworks in the U.S.
  • 5.1.2 Legal Requirements and Frameworks in Europe
  • 5.1.3 Legal Requirements and Frameworks in Asia-Pacific
    • 5.1.3.1 Legal Requirements and Framework in China
    • 5.1.3.2 Legal Requirements and Framework in Japan

6. Global Gene Fusion Testing Market: Market Dynamics

• 6.1 Impact Analysis
• 6.2 Market Drivers
• 6.3 Market Restraints
• 6.4 Market Opportunities

7. Global Gene Fusion Testing Market: Competitive Insights

• 7.1 Overview
• 7.2 Key Strategies and Developments
  • 7.2.1 Product Approvals and Launches
  • 7.2.2 Partnerships and Collaborations
  • 7.2.3 Mergers and Acquisitions
  • 7.2.4 Other Developments
• 7.3 Market Share Analysis
  • 7.3.1 By Company
• 7.4 Growth-Share Analysis

8. Global Gene Fusion Testing Market (by Category), ($Million), 2023-2035

• 8.1 Overview
• 8.2 Research
• 8.3 Diagnostic

9. Global Gene Fusion Testing (by Technology), ($Million), 2023-2035

• 9.1 Overview
• 9.2 Next-Generation Sequencing (NGS)
• 9.3 Fluorescence In-Situ Hybridization (FISH)
• 9.4 Polymerase Chain Reaction (PCR)
• 9.5 Immunohistochemistry (IHC)

10. Global Gene Fusion Testing Market (by Indication), ($Million), 2023-2035

• 10.1 Overview
• 10.2 Solid Tumors
  • 10.2.1 Lung Cancer
  • 10.2.2 Breast Cancer
  • 10.2.3 Colorectal Cancer
  • 10.2.4 Thyroid Cancer
  • 10.2.5 Others
• 10.3 Hematological Malignancies

11. Global Gene Fusion Testing Market (by End User), ($Million), 2023-2035

• 11.1 Overview
• 11.2 Pharmaceutical and Biotechnology Companies
• 11.3 Hospitals and Diagnostic Laboratories
• 11.4 Research and Academic Centers

12. Global Gene Fusion Testing Market (by Region), ($Million), 2023-2035

• 12.1 Overview
• 12.2 North America
  • 12.2.1 North America Gene Fusion Testing Market, by Indication
  • 12.2.2 North America Gene Fusion Testing Market (by Country)
    • 12.2.2.1 U.S.
      • 12.2.2.1.1 U.S. Gene Fusion Testing Market (by Indication)
    • 12.2.2.2 Canada
      • 12.2.2.2.1 Canada Gene Fusion Testing Market (by Indication)
• 12.3 Europe
  • 12.3.1 Europe Gene Fusion Testing Market, by Indication
  • 12.3.2 Europe Gene Fusion Testing Market (by Country)
    • 12.3.2.1 Germany
      • 12.3.2.1.1 Germany Gene Fusion Testing Market (by Indication)
    • 12.3.2.2 France
      • 12.3.2.2.1 France Gene Fusion Testing Market (by Indication)
    • 12.3.2.3 U.K.
      • 12.3.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
    • 12.3.2.4 Italy
      • 12.3.2.4.1 Italy Gene Fusion Testing Market (by Indication)
    • 12.3.2.5 Spain
      • 12.3.2.5.1 Spain Gene Fusion Testing Market (by Indication)
    • 12.3.2.6 Netherlands
      • 12.3.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
    • 12.3.2.7 Rest-of-the-Europe
      • 12.3.2.7.1 Rest-of-the-Europe Gene Fusion Testing Market (by Indication)
• 12.4 Asia-Pacific
  • 12.4.1 Asia-Pacific Gene Fusion Testing Market, by Indication
  • 12.4.2 Asia-Pacific Gene Fusion Testing Market (by Country)
    • 12.4.2.1 China
      • 12.4.2.1.1 China Gene Fusion Testing Market (by Indication)
    • 12.4.2.2 Japan
      • 12.4.2.2.1 Japan Gene Fusion Testing Market (by Indication)
    • 12.4.2.3 India
      • 12.4.2.3.1 India Gene Fusion Testing Market (by Indication)
    • 12.4.2.4 Australia
      • 12.4.2.4.1 Australia Gene Fusion Testing Market (by Indication)
    • 12.4.2.5 South Korea
      • 12.4.2.5.1 South Korea Fusion Testing Market (by Indication)
    • 12.4.2.6 Rest-of-Asia-Pacific
      • 12.4.2.6.1 Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication)
• 12.5 Latin America
  • 12.5.1 Latin America Gene Fusion Testing Market, by Indication
  • 12.5.2 Latin America Gene Fusion Testing Market (by Country)
    • 12.5.2.1 Brazil
      • 12.5.2.1.1 Brazil Gene Fusion Testing Market (by Indication)
    • 12.5.2.2 Mexico
      • 12.5.2.2.1 Mexico Gene Fusion Testing Market (by Indication)
    • 12.5.2.3 Rest-of-Latin America
      • 12.5.2.3.1 Rest-of-Latin America Gene Fusion Testing Market (by Indication)
• 12.6 Rest-of-the-World
  • 12.6.1 Rest-of-the-World Gene Fusion Testing Market (by Indication)

13. Competitive Landscape and Company Profiles

• 13.1 Competitive Landscape
  • 13.1.1 New Offerings
  • 13.1.2 Mergers and Acquisitions
  • 13.1.3 Partnerships, Alliances, and Business Expansion
  • 13.1.4 Funding Activities
  • 13.1.5 Regulatory Approvals
• 13.2 Amoy Diagnostics Co., Ltd.
  • 13.2.1 Overview
  • 13.2.2 Type Portfolio
  • 13.2.3 Target Customers
  • 13.2.4 Key Professionals
  • 13.2.5 Analyst View
• 13.3 Arima Genomics
  • 13.3.1 Overview
  • 13.3.2 Product Portfolio
  • 13.3.3 Target Customers
  • 13.3.4 Key Professionals
  • 13.3.5 Analyst View
• 13.4 Biocartis
  • 13.4.1 Overview
  • 13.4.2 Product Portfolio
  • 13.4.3 Target Customers
  • 13.4.4 Key Professionals
  • 13.4.5 Analyst View
• 13.5 Biocare Medical, LLC
  • 13.5.1 Overview
  • 13.5.2 Product Portfolio
  • 13.5.3 Target Customers
  • 13.5.4 Key Professionals
  • 13.5.5 Analyst View
• 13.6 Bio-Rad Laboratories, Inc.
  • 13.6.1 Overview
  • 13.6.2 Product Portfolio
  • 13.6.3 Target Customers
  • 13.6.4 Key Professionals
  • 13.6.5 Analyst View
• 13.7 F. Hoffmann-La Roche Ltd
  • 13.7.1 Overview
  • 13.7.2 Product Portfolio
  • 13.7.3 Target Customers
  • 13.7.4 Key Professionals
  • 13.7.5 Analyst View
• 13.8 Guardant Health, Inc
  • 13.8.1 Overview
  • 13.8.2 Product Portfolio
  • 13.8.3 Target Customers
  • 13.8.4 Key Professionals
  • 13.8.5 Analyst View
• 13.9 Illumina, Inc.
  • 13.9.1 Overview
  • 13.9.2 Product Portfolio
  • 13.9.3 Target Customers
  • 13.9.4 Key Professionals
  • 13.9.5 Analyst View
• 13.10 Invitae Corporation
  • 13.10.1 Overview
  • 13.10.2 Product Portfolio
  • 13.10.3 Target Customers
  • 13.10.4 Key Professionals
  • 13.10.5 Analyst View
• 13.11 Myriad Genetics, Inc.
  • 13.11.1 Overview
  • 13.11.2 Product Portfolio
  • 13.11.3 Target Customers
  • 13.11.4 Key Professionals
  • 13.11.5 Analyst View
• 13.12 NeoGenomics, Inc.
  • 13.12.1 Overview
  • 13.12.2 Product Portfolio
  • 13.12.3 Target Customers
  • 13.12.4 Key Professionals
  • 13.12.5 Analyst View
• 13.13 OncoDNA
  • 13.13.1 Overview
  • 13.13.2 Product Portfolio
  • 13.13.3 Target Customers
  • 13.13.4 Key Professionals
  • 13.13.5 Analyst View
• 13.14 PerkinElmer, Inc.
  • 13.14.1 Overview
  • 13.14.2 Product Portfolio
  • 13.14.3 Target Customers
  • 13.14.4 Key Professionals
  • 13.14.5 Analyst View
• 13.15 QIAGEN N.V.
  • 13.15.1 Overview
  • 13.15.2 Product Portfolio
  • 13.15.3 Target Customers
  • 13.15.4 Key Professionals
  • 13.15.5 Analyst View
• 13.16 Thermo Fisher Scientific Inc.
  • 13.16.1 Overview
  • 13.16.2 Product Portfolio
  • 13.16.3 Target Customers
  • 13.16.4 Key Professionals
  • 13.16.5 Analyst View